Journal Mobile Options
Table of Contents
Vol. 106, No. 1-2, 2001
Issue release date: September 2001
Section title: Paper
Acta Haematol 2001;106:25–32
(DOI:10.1159/000046586)

Update on Tumor Cell Procoagulant Factors

Gale A.J. · Gordon S.G.
aDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, Calif., and bDepartment of Biology, San Diego State University, San Diego, Calif., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 9/12/2001

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 0

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: http://www.karger.com/AHA

Abstract

Tumor cells produce tissue factor, cancer procoagulant, plasminogen activators and other factors that interact with the coagulation system, the fibrinolytic system and vascular or blood cells such that they can upset the normal homeostasis and balance between activation and inhibition of the coagulation and fibrinolytic systems. These activities play a role in tumor cell growth and metastasis, vascular wall function, and hemostasis. Proteases and their inhibitors are intimately involved in all aspects of the hemostatic, cell proliferation and cellular signalling systems. This review provides a brief examination of recent observations in this complex interaction of cellular and hemostatic factors.


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 9/12/2001

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 0

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: http://www.karger.com/AHA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Trousseau A: Plegmasia alba dolens; in Clinique médicale de l’Hôtel-Dieu de Paris. London, The New Sydenham Society, 1865, p 94.
  2. Dvorak HF: Abnormalities of hemostasis in malignant disease; in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Lippincott, 1994, pp 1238–1254.
  3. Green KB, Silverstein RL: Hypercoagulability in cancer. Hematol Oncol Clin North Am 1996;10:499–530.
  4. Carmeliet P, Collen D: Tissue factor. Int J Biochem Cell Biol 1998;30:661–667.
  5. Gordon SG: Cancer cell procoagulants and their role in malignant disease. Semin Thromb Hemost 1992;18:424–433.
  6. Gordon SG, Mielicki WP: Cancer procoagulant: A factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 1997;8:73–86.
  7. Bazan JF: Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934–6938.
  8. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Demunck H, Kasper M, Breier G, Evrard P, Muller M, Risau W, Edgington T, Collen D: Role of tissue factor in embryonic blood vessel development. Nature 1996;383:73–75.
  9. Ruf W, Mueller BM: Tissue factor signaling. Thromb Haemost 1999;82:175–182.
  10. Ruf W, Mueller BM: Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996;3:379–384.
  11. Rao LV, Pendurthi UR: Tissue factor on cells. Blood Coagul Fibrinolysis 1998;9(suppl 1):S27–S35.
  12. Osterud B: Tissue factor expression by monocytes: Regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998;9(suppl 1):S9–S14.
  13. Nemerson Y, Giesen PL: Some thoughts about localization and expression of tissue factor. Blood Coagul Fibrinolysis 1998;9(suppl 1):S45–S47.
  14. Bach RR: Mechanism of tissue factor activation on cells. Blood Coagul Fibrinolysis 1998;9(suppl 1):S37–S43.
  15. Semeraro N, Colucci M: Tissue factor in health and disease. Thromb Haemost 1997;78:759–764.
  16. Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Passerini CG, Gordon SG, Barbui T: Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1998;92:143–151.
  17. Zhu J, Guo WM, Yao YY, Zhao WL, Pan L, Cai X, Ju B, Sun GL, Wang HL, Chen SJ, Chen GQ, Caen J, Chen Z, Wang ZY: Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia 1999;13:1062–1070.

    External Resources

  18. Morrissey JH, Fakhrai H, Edgington TS: Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987;50:129–135.
  19. Harlos K, Martin DM, O’Brien DP, Jones EY, Stuart DI, Polikarpov I, Miller A, Tuddenham EG, Boys CW: Crystal structure of the extracellular region of human tissue factor. Nature 1994;370:662–666.
  20. Muller YA, Ultsch MH, Kelley RF, de Vos AM: Structure of the extracellular domain of human tissue factor: Location of the factor VIIa binding site. Biochemistry 1994;33:10864–10870.

    External Resources

  21. Banner DW, D’Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D: The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996;380:41–46.
  22. Bom VJ, Bertina RM: The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J 1990;265:327–336.

    External Resources

  23. Lawson JH, Butenas S, Mann KG: The evaluation of complex-dependent alterations in human factor VIIa. J Biol Chem 1992;267:4834–4843.

    External Resources

  24. Ruf W: The interaction of activated factor VII with tissue factor: Insight into the mechanism of cofactor-mediated activation of activated factor VII. Blood Coagul Fibrinolysis 1998;9(suppl 1):S73–S78.
  25. Davie EW, Fujikawa K, Kisiel W: The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991;30:10363–10370.

    External Resources

  26. Sawada M, Miyake S, Ohdama S, Matsubara O, Masuda S, Yakumaru K, Yoshizawa Y: Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 1999;79:472–477.
  27. Seto S, Onodera H, Kaido T, Yoshikawa A, Ishigami S, Arii S, Imamura M: Tissue factor expression in human colorectal carcinoma: Correlation with hepatic metastasis and impact on prognosis. Cancer 2000;88:295–301.
  28. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H: Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998;80:894–898.
  29. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T: Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration. Br J Cancer 2000;83:164–170.
  30. Mueller BM, Reisfeld RA, Edgington TS, Ruf W: Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992;89:11832–11836.
  31. Kakkar AK, Chinswangwatanakul V, Lemoine NR, Tebbutt S, Williamson RC: Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg 1999;86:890–894.
  32. Poulsen LK, Jacobsen N, Sorensen BB, Bergenhem NC, Kelly JD, Foster DC, Thastrup O, Ezban M, Petersen LC: Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem 1998;273:6228–6232.
  33. Rottingen JA, Enden T, Camerer E, Iversen JG, Prydz H: Binding of human factor VIIa to tissue factor induces cytosolic Ca2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. J Biol Chem 1995;270:4650–4660.
  34. Camerer E, Rottingen JA, Gjernes E, Larsen K, Skartlien AH, Iversen JG, Prydz H: Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem 1999;274:32225–32233.
  35. Pendurthi UR, Alok D, Rao LV: Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: Up-regulation of poly(A) polymerase. Proc Natl Acad Sci USA 1997;94:12598–12603.
  36. Pendurthi UR, Allen KE, Ezban M, Rao LV: Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa · tissue factor-induced signal transduction. J Biol Chem 2000;275:14632–14641.
  37. Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H: Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 2000;275:6580–6585.
  38. Mueller BM, Ruf W: Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998;101:1372–1378.
  39. Sorensen BB, Freskgard PO, Nielsen LS, Rao LV, Ezban M, Petersen LC: Factor VIIa-induced p44/42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain. J Biol Chem 1999;274:21349–21354.
  40. Esumi N, Fan D, Fidler IJ: Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 1991;51:4549–4556.

    External Resources

  41. Fischer EG, Ruf W, Mueller BM: Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 1995;55:1629–1632.
  42. Camerer E, Huang W, Coughlin SR: Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000;97:5255–5260.
  43. Coughlin SR: How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999;96:11023–11027.
  44. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A: Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995;92:8205–8209.
  45. Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH: Role of tissue factor in metastasis: Functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999;82:88–92.
  46. Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W: A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998;140:1241–1253.
  47. Fischer EG, Riewald M, Huang HY, Miyagi Y, Kubota Y, Mueller BM, Ruf W: Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest 1999;104:1213–1221.
  48. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000;407:249–257.
  49. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320–1327.
  50. Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, Humphrey PA, Catalona WJ, Milbrandt J: Tissue factor expression and angiogenesis in human carcinoma. Hum Pathol 2000;31:443–447.
  51. Koomagi R, Volm M: Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: Correlation between tissue factor and angiogenesis. Int J Cancer 1998;79:19–22.
  52. Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN, Danave I, Dillehay DL, Matthews E, Contrino J, Morrissey JH, Gordon S, Edgington TS, Kudryk B, Kreutzer DL, Rickles FR: Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998;152:399–411.
  53. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR: Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96:8663–8668.
  54. Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D: Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998;91:2698–2703.
  55. Ollivier V, Chabbat J, Herbert JM, Hakim J, de Prost D: Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol 2000;20:1374–1381.
  56. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D: Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535–1545.
  57. Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK, Pinedo HM: Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000;6:166–171.
  58. Parry GC, Mackman N: Mouse embryogenesis requires the tissue factor extracellular domain but not the cytoplasmic domain. J Clin Invest 2000;105:1547–1554.

    External Resources

  59. Gordon SG, Franks JJ, Lewis BJ: Comparison of procoagulant activities in extracts of normal and malignant human tissue. J Natl Cancer Inst 1979;62:773–776.

    External Resources

  60. Gordon SG, Hasiba U, Cross BA, Poole MA, Falanga A: Cysteine proteinase procoagulant from amnion-chorion. Blood 1985;66:1261–1265.

    External Resources

  61. Falanga A, Gordon SG: Isolation and characterization of cancer procoagulant: A cysteine proteinase from malignant tissue. Biochemistry 1985;24:5558–5567.

    External Resources

  62. Gordon SG, Cross BA: A factor X-activating cysteine protease from malignant tissue. J Clin Invest 1981;67:1665–1671.

    External Resources

  63. Gordon SG, Mourad AM: The site of activation of factor X by cancer procoagulant. Blood Coagul Fibrinolysis 1991;2:735–739.
  64. Mielicki WP, Kozwich DL, Kramer LC, Gordon SG: Effect of divalent ions on the activity of cancer procoagulant. Arch Biochem Biophys 1994;314:165–170.
  65. Mielicki WP, Tagawa M, Gordon SG: New immunocapture enzyme (ICE) assay for quantification of cancer procoagulant activity: Studies of inhibitors. Thromb Haemost 1994;71:456–460.
  66. Barrett AJ, Kembhavi AA, Brown MA, Kirschke H, Knight CG, Tamai M, Hanada K: L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J 1982;201:189–198.

    External Resources

  67. Mielicki WP, Sobolewska M: Cancer procoagutant (EC 3.4.22.26): The kinetics of its inhibition by E-64 and modulation of the activity by cadmium, copper and tin ions. Cancer Res Ther Control 2001;11:135–141.
  68. Kembhavi AA, Buttle DJ, Rauber P, Barrett AJ: Clostripain: Characterization of the active site. FEBS Lett 1991;283:277–280.
  69. Francis JL, Biggerstaff J, Amirkhosravi A: Hemostasis and malignancy. Semin Thromb Hemost 1998;24:93–109.
  70. Arkel YS: Thrombosis and cancer. Semin Oncol 2000;27:362–374.
  71. Falanga A, Rickles FR: Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999;25:173–182.
  72. Kakkar AK, de Lorenzo F, Pineo GF, Williamson RC: Venous thromboembolism and cancer. Baillières Clin Haematol 1998;11:675–687.

    External Resources

  73. Gordon SG, Cross BA: An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Cancer Res 1990;50:6229–6234.
  74. Kozwich DL, Kramer LC, Mielicki WP, Fotopoulos SS, Gordon SG: Application of cancer procoagulant as an early detection tumor marker. Cancer 1994;74:1367–1376.
  75. Mielicki WP, Tenderenda M, Rutkowski P, Chojnowski K: Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. Cancer Lett 1999;146:61–66.
  76. Olas B, Wachowicz B, Mielicki WP, Buczynski A: Free radicals are involved in cancer procoagulant-induced platelet activation. Thromb Res 2000;97:169–175.
  77. Olas B, Mielicki WP, Wachowicz B, Krajewski T: Cancer procoagulant stimulates platelet adhesion. Thromb Res 1999;94:199–203.
  78. Inufusa H, Adachi T, Suzuki M, Ando O, Ohta T, Kurimoto M, Nakatani Y, Nakamura M, Yasutomi M: Generation of a monoclonal antibody that inhibits the procoagulant activity of various cancer cell lines. Cancer 1998;82:1563–1569.
  79. Kalweit GA, Feindt P, Micek M, Gams E, Hellstern P: Markers of activated hemostasis and fibrinolysis in patients with pulmonary malignancies: Comparison of plasma levels in central venous and pulmonary venous blood. Thromb Res 2000;97:105–111.
  80. Wojtukiewicz MZ, Rucinska M, Zimnoch L, Jaromin J, Piotrowski Z, Rozanska-Kudelska M, Kisiel W, Kudryk BJ: Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res 2000;97:335–342.
  81. Lwaleed BA, Chisholm M, Francis JL: Urinary tissue factor levels in patients with breast and colorectal cancer. J Pathol 1999;187:291–294.